COYA-101

N/A

Report date: 2023/04/04 18:04:46

Base Information

Drug NameCOYA-101

Drug Alias NameT-regulatory CellsCOYA-101ALS001ALS-001

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tregs

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsAmyotrophic Lateral Sclerosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesCoya Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesCoya Therapeutics Inc

Inactive CompaniesThe Center For Clinical And Translational Sciences (Ccts) Clinical Research Unit At The University Of Texas Health Science Center At Houston

Active IndicationsAmyotrophic Lateral Sclerosis

Inactive IndicationsN/A

Other Information

ATC CodeN/A